RTI Biologics, Inc. (RTIX) Tops Q2 EPS by 1c; Guides Q3; Adjusts FY12 Numbers

Article Stock Quotes (1) Comments (0)

RTI Biologics, Inc. (NASDAQ: RTIX) reported Q2 EPS of $0.05, $0.01 better than the analyst estimate of $0.04. Revenue for the quarter came in at $45.2 million versus the consensus estimate of $44.24 million.

RTI Biologics, Inc. sees FY2012 EPS of $0.14-$0.15, versus prior guidance of $0.16-$0.17 and the consensus of $0.17. RTI Biologics, Inc. sees FY2012 revenue of $177-$178 million, versus prior guidance of $176-$178 million and the consensus of $177.24 million.

Sees Q3 2012 revenue of $44-$45 million, versus the consensus of $43.49 million.

For earnings history and earnings-related data on RTI Biologics, Inc. (RTIX) click here.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• UPDATE: Applied Materials, Inc. (AMAT) Tops Q2 EPS by 3c, Offers Guidance
• Stage Stores, Inc. (SSI) Posts Surprise Q1 Loss of 2c/Share
• 21Vianet Group (VNET) Misses Q1 EPS by 4c

Create E-mail Alert Related Categories

Earnings, Guidance, Hot Guidance

Related Entities

Earnings

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?